Extensively drug-resistant tuberculosis: A case report and literature review

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 5, 2008, Pages 447-452

  de Araújo Filho, João Alves ^a,b   Vasconselos Jr , Arioldo Carvalho ^a   de Sousa, Eduardo Martins ^a   da Silveira, Colombina ^b   Ribeiro, Elisangela ^c   Kipnis, André ^a   Junqueira Kipnis, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b Tropical Diseases Hospital Dr Anuar Auad   (Brazil)

^c Araújo Jorge Hospital   (Brazil)

Author keywords

Extensively drug resistant tuberculosis; Mycobacterium tuberculosis; Tuberculosis; XDR TB

Indexed keywords

AMIKACIN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BRAZIL; BRONCHOPLEURAL FISTULA; CASE REPORT; DEATH; DRUG HYPERSENSITIVITY; DRUG RESISTANT TUBERCULOSIS; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LUNG INJURY; LUNG LOBECTOMY; LUNG TUBERCULOSIS; MALE; MULTIPLE ORGAN FAILURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROGNOSIS; SEPSIS; TUBERCULOUS EMPYEMA; DRUG EFFECT; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FATALITY; ISOLATION AND PURIFICATION; MIDDLE AGED; REVIEW;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 65449153671     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702008000500019     Document Type: Article

References (26)

1. World Health Organization. WHO REPORT 2007: Global Tuberculosis Control: Surveillance, Planning, Financing. Geneve; 2007.
2. Maartens G., Wilkinson R. Tuberculosis. Lancet 2007;370:2030-43.
3. Meya D.B., McAdam K.P.W.J. The TB pandemic: an old problem seeking new solutions. J Intern Med 2004;261:309-29.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2006.
5. Center for Diseases Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to secondline drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5.
6. World Health Organization. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec 2006;42:408.
7. World Health Organization. Tuberculosis. XDR-TB - The facts. Available at http://www.who.int/tb/challenges/xdr/facts∉v2007_en.pdf. Accessed January 10, 2008.
8. Gandhi N.R., Moll A., Sturm A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
9. Kim H.R., Hwang S.S., Kim H.J., et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-5
10. Cox H.S., Kalon S., Allamuratova S., et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS ONE 2007; 2(11):e1126.
11. Raviglione M.C., Smith I.M. XDR tuberculosis - implications for global public health. N Engl J Med 2007;356(7):656-9.
12. Ebrahim G.J. Drug resistance in tuberculosis. J Trop Pediatr 2007; 53:147-9.
13. Lawn S.D., Wilkinson R. Extensively drug resistant tuberculosis. A serious wake-up call for global health. BMJ 2006;333:560-1.
14. Weis S.E., Slocum P.C., Blais F.X., et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330(17):1179-84.
15. Jasmer R.M., Seaman C.B., Gonzalez L.C., et al. Tuberculosis treatment outcomes. Directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004;170:561-6.
16. Ministério da Saúde. Tuberculose multirresistente - Guia de vigilância epidemiológica. Rio de Janeiro: Ministério da Saúde; 2007.
17. Basu S., Andrews J.A., Poolman E.M., et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in South African district hospitals: an epidemiological modelling study. Lancet 2007;370:1500-7.
18. Goemaere E., Ford N., Berman D., McDermid C., Cohen R. XDRTB in South Africa: detention is not the priority. PLoS Medicine 2007; 4(4):772-3.
19. O'brien R.J., Nunn P.P. The need for new drugs against tuberculosis. Obstacles, oppurtunities, and next steps. Am J Respir Crit Care Med 2001;162:1055-8.
20. Spigelman M., Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006;367:945-6.
21. Souza M.V.N., Vasconcelos T.R.A. Fármacos no combate à tuberculose: passado, presente e futuro. Quimica Nova 2005; 28(4):678-82.
22. Duncan K., Barry III C.E. Prospects for new antibercular drugs. Curr Opin Microbiol 2004;7:460-5.
23. Parmet W.E. Legal power and legal rights - isolation and quarantine in the case of drug-resistant tuberculosis. N Engl J Med 2007; 375(5):433-5.
24. Porco T.C., Getz W.M. Controlling extensively drug-resistant tuberculosis. Lancet 2007;370:1464-5.
25. Singh J.A., Upshur R., Padayatchi N. XDR-TB in South Africa: no time for denial or complacency. PLoS Medicine 2007;4(1):19-25.
26. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006;45:430-2.